Genmab — April 2011
-
jeg siger også tak
-
Genmab pænt luk i 58
-
emerging role. fra d. 24 . marts
-
-
-
For patients who finished all 6 of the planned 6 cycles of FCO, the overall response rate jumped to 92% and the “CR” rate jumped to 56%.
-
måske er arzerra bedre end ritux. Det er ihvertfald too close to call. Min konklusion. Arzerra vil spille en rolle på markedet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind